Key result
Vasopressin shows promise for vasodilatory shock but routine clinical use awaits randomized trials.
Why the study?
Does vasopressin improve outcomes such as organ failure and mortality in patients with vasodilatory shock?
Population
Patients with vasodilatory shock states
Design
Review
Authors
Loading...
Caution against routine vasopressin use in vasodilatory shock; leaves open its impact on mortality and organ failure pending RCTs.
Does vasopressin improve outcomes such as organ failure and mortality in patients with vasodilatory shock?
While vasopressin is an emerging therapy for vasodilatory shock, its routine clinical use should await randomized controlled trials evaluating hard outcomes like mortality and organ failure.
Holmes et al. (2003) conducted a review in Vasodilatory shock states. Vasopressin was evaluated. Vasopressin is emerging as a therapy for vasodilatory shock, but routine clinical use should await randomized controlled trials evaluating its effect on organ failure and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: